CD phenotype stratified by the FOXO3A rs12212067 genotype in CD patients carrying none of the three NOD2 mutations analyzed (NOD2 wild-type).

Group (1): CD patients carrying the rs12212067 T variant in homozygous form (219 patients with the TT genotype and no further NOD2 mutant), group (2): CD patients with the FOXO3A rs12212067 GG or TG genotype and no further NOD2 mutation.1According to the Montreal classification, a stricturing disease phenotype was defined as the presence of a stenosis without penetrating disease. The diagnosis of stenoses was made surgically, endoscopically, or radiologically (using MR enteroclysis).2Immunosuppressive agents included azathioprine, 6-mercaptopurine, methotrexate, infliximab, and/or adalimumab.3Only surgery related to CD-specific problems (e.g., ileocecal resection, fistulectomy, colectomy, and ileostomy) was included.CD phenotype stratified by the FOXO3A rs12212067 genotype in CD patients carrying none of the three NOD2 mutations analyzed (NOD2 wild-type).